Veraxa Biotech is scheduled to announce at Veraxa Biotech in the United States in the United States through a merging process with Voyageer Councition Corp, a SPAC.
The deal, which is expected to be closed in the fourth quarter 2025, will be included in the Nasdaq Stock Exchange, and it shall be traded under the Verx code. The deal also allows Ferraka to the American capital markets, as it continues to expand its pipeline from targeted cancer treatments.
The merger of the joint entity is estimated at about $ 1.64 billion on the basis of Pro Forma, assuming that the shareholders are not recovered. Under the terms of the agreement, Verksa shareholders will receive about 130 million shares in the newly formed company, at a price of $ 10 per share. The value of the contribution of property rights in Ferraka is about $ 1.3 billion.
Upon completion of the transaction, Veraxa will be able to reach about $ 253 million currently in the Voyageer TRST account. The company also plans to follow an additional financing round to enhance its cash reserves and support continuous research and development efforts.
Veraxa is established and incubated by the Swiss Investment Company XLIFE Sciences, and the development of a group of antibodies based on antibodies, including anti -drug comparison (ADC) and privacy cells. The main clinical assets VX-A901 are the FLT antibodies in experiments in the early stage of malignant tumors. The candidate was added to the Ferraksa pipeline after the company acquired SYNIMMUNE for 2024.
The primary innovation in Ferraksa lies in the bitac cell platform (BITAC). This technology is designed to enhance the integrity and privacy of antibody -based cancer treatments. It uses a bilateral approach to antibodies that make up an active therapeutic molecule when both antibodies simultaneously associated with distinctive goals associated with the tumor. This proximity stimulant mechanism aims to reduce toxicity outside the target-which is common restrictions on current immune diseases.
The company currently has three BITAC programs in pre -clinical development. Two of these targeted lung and pancreas cancers, while the third is aimed at ovarian and breast cancers. Verksa said it would follow strategic partnerships and multiple licensing opportunities in 2025 and 2026.
“The side effects of cancer treatments today and prevent doctors from applying the optimal dose levels.
Voyageer Voyager Hosenion Chairman has noticed increasing interest in ADC and two -century antibody treatments as part of the logical basis for integration. “We believe that the next generation of ADCS and Bispecifics will continue to revolutionize oncology, due to its significant improvement in the level of care treatments and the high possibility of technical and organizational success compared to other oncology drugs, as it is clear from multiple deals in excess of one billion dollars each since 2023 in this field.”
According to Globaldata numbers, the value of the anti -drug drug market was $ 8.6 billion in 2023, with expectations to overcome them 45 billion dollars by 2030.
Globaldata is the parent company of Pharmaceutical technology.
Modern transactions in the area support positive expectations. In October 2023, MSD A joint development deal entered With Daiichi Sankyo worth $ 22 billion for three ADC assets. Almost at the same time, GSK got exclusive rights for the ADC candidate in the DB-1324 digestive system in a deal exceeding one billion dollars. In March 2025, Sanofi announced that it would work Drenn Bio’s specific antibodies Dr-2013 for $ 1.9 billion.
Other major ADC transactions include a $ 1 billion license agreement between Danish biotechnology Adcento and the public in China -based China For ADCE-T02, ADC targeting the tissue factor.
“Veraxa to Spinies in a $ 1.6 billion in SPAC deal with Voyageer” was originally created and published by Pharmaceutical technologyThe brand owned by Globaldata.
Information on this site was included in good faith for public media purposes only. It is not intended to reach the advice that you should depend on, and we do not provide any representation, guarantee or guarantee, whether it is explicit or implicit in relation to accurately or completing it. You must have a professional or specialized advice before taking any action based on the content on our website.
The post Veraxa to go public in $1.6bn SPAC deal with Voyager first appeared on Investorempires.com.
